复宏汉霖与山德士达成HLX13全球商业化合作协议

iDoNews
30 Apr

4月29日,复宏汉霖宣布与山德士签署授权协议,授予后者其自主研发的伊匹木单抗生物类似药HLX13在欧美、日本等主要市场的独家商业化权益。根据协议,复宏汉霖将主导HLX13的研发、生产及供应,并有望通过里程碑付款获得3.01亿美元收入,首付款达3100万美元。HLX13作为复宏汉霖核心生物类似药管线产品,其原研药Yervoy是全球首个CTLA-4抑制剂,已获批用于治疗黑色素瘤、肝细胞癌等多种适应症。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10